Skip to main content
Clinical Trials/NCT06586034
NCT06586034
Not yet recruiting
Not Applicable

Culturally-Adapted Smoking Cessation Mobile App for Hispanic Individuals Who Smoke

University of Houston0 sites56 target enrollmentApril 2025

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Smoking Cessation
Sponsor
University of Houston
Enrollment
56
Primary Endpoint
7-Day Point Prevalence Smoking Abstinence
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

The specific aims of the project are to develop and test a mobile application for smoking cessation for Hispanic individuals who smoke called Impacto.

Detailed Description

A total of 56 Hispanic individuals who smoke will be recruited for this project. Six (6) participants will complete usability/functionality testing of Impacto 2.0 in the English language for both iOS and Android. Following usability/functionality testing, a field test with 50 adult Hispanic individuals who smoke (50% English-speaking and 50% Spanish-speaking) will be recruited nationally and will receive Impacto 2.0 (50% Android and iOS platforms).

Registry
clinicaltrials.gov
Start Date
April 2025
End Date
March 2026
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Michael J. Zvolensky, Ph.D.

Hugh Roy and Lillie Cranz Cullen Distinguished University Professor

University of Houston

Eligibility Criteria

Inclusion Criteria

  • being Hispanic, 2) at least 18 years of age, 2) currently smoking (i.e., at least 5 cigarettes/day) biochemically verified by a CO \> 7, 3), meeting criteria for high AS (cut-off score of 5 on the Short Scale Anxiety Sensitivity Index), 4) motivation to quit \> 5 on a 10 pt. scale, 5) able to provide informed consent, 6) has daily access to their own iPhone or Android smartphone, and 7) is a fluent English or Spanish speaker.

Exclusion Criteria

  • current participation in substance abuse treatment, 2) in psychotherapy for anxiety or depression, 3) concurrent use of medication for anxiety or depression, 4) active suicidality (ideation, intent, and/or plan), or 5) current psychosis.

Outcomes

Primary Outcomes

7-Day Point Prevalence Smoking Abstinence

Time Frame: End of treatment (Week 8)

7-day point prevalence smoking status (verification via carbon monoxide).

Secondary Outcomes

  • Anxiety Sensitivity(Baseline, week 4, and end of treatment (Week 8))

Similar Trials